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INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSES OF 
RADIATION-INDUCED MALIGNANCIES 
YONG EUN LEE 
ABSTRACT 
 Cancer is a genetic disease caused by an unregulated expansion of a 
clone of cells (Sompayrac, 2004). The genetic abnormalities in cancer are the 
consequences of defective DNA replication, repair, maintenance, and 
modification, genetic background, and exposure to mutagens (Alexandrov et al., 
2013).  
 Ionizing radiation (IR), a mutagen exposed to cancer patients during 
clinical radiotherapy (RT), can cause DNA damage, genomic instability, and 
mutagenesis (Sherborne et al., 2015). While RT has been effective in treating 
cancer, it increases the risk of second malignant neoplasm (SMN), a severe 
delayed complication associated with mainly pediatric cancer survivors many 
decades after the treatment of their first cancer (Robison & Hudson, 2014). As 
the mortality of patients with childhood cancer has been decreasing, cases of 
radiation-induced cancers has been increasing (Robison & Hudson, 2014). The 
considerable contribution by RT to SMN risk illustrate the need to characterize 
the genetic mechanism directly responsible for radiation-induced malignancies.  
 To better our understanding of the mutational landscape of SMNs, our 
specific aims are to identify potential driver mutations implicated in radiation-
induced malignancies through genome and transcriptome analysis and to assess 
		 vii 
whether genetic background, specifically germline polymorphisms and mutations 
in tumor suppressor gene TP53, has an impact on the formation of secondary 
malignancies.   
		 viii 
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INTRODUCTION 	
Cancer is a major public health problem in United States. According to 
DeSantis et al., about 589,430 Americans died in 2015 from cancer, listing as the 
second leading cause of death following heart disease.  The most common 
cancers are lung and bronchus, prostate, and colorectum amongst men, and 
lung and bronchus, breast, and colorectum in women (DeSantis et al., 2014).  
While men are more likely to be diagnosed with cancer than women in their 
lifetime, cancer risk is higher for women than men under the age of 50 (Siegel, 
Miller, & Jemal, 2015).  Incidence of childhood and adolescent cancer makes 1% 
of cancer diagnoses; leukemia and cancers of the central nervous system 
accounts for 50% of these cases (Robison & Hudson, 2014).  Because cancer is 
very diverse with over 100 identified types with different causes and symptoms  
(Almeida & Barry, 2011), the disease is difficult to cure.  A tumor can form in any 
tissue type; while many commonalities exist, each cancer is unique (Almeida & 
Barry, 2011).  
In the most basic sense, cancer can be defined as a disease in which a 
group of unregulated cells grow abnormally, ignoring all the rules of cell division 
(Hejmadi, 2009). The normal cells transform into cancer cells that disrupt the 
molecular networks that control cell proliferation, differentiation, and 
death(Hejmadi, 2009).  When this proliferation persists, the tumor grows and 
metastasizes, which makes up 90% of cancer-related deaths (Hejmadi, 2009).  
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Cancer pathogenesis is caused by somatic mutations that allow a clone of 
cells to grow in an unregulated fashion (Stratton, 2011).  Somatic mutations 
include base substitutions, insertions and deletions (indels), and structural 
variations such as copy-number variations, translocations, inversions, and copy-
neutral regions of loss of heterogeneity (cnLOH) (Stratton, 2011).  While somatic 
mutations exist in all cells, a subset called driver mutations contribute to the 
cancer phenotype by altering tumor suppressor genes and oncogenes (also 
known as recessive and dominant cancer genes, respectively) that normally 
regulate cell growth, proliferation, differentiation, and death (Stratton, 2011).  An 
individual’s likelihood of acquiring driver mutations depends on exogenous and 
endogenous mutagenic exposures and predisposed germline mutations 
(Alexandrov et al., 2013).  For example, exposure to cigarette smoke and 
ultraviolet radiation are major risk factors of lung cancer and skin cancer, 
respectively (International Agency for Research on Cancer Working Group on 
artificial ultraviolet (UV) light and skin cancer, 2007; Pirozynski, 2006), and 
overexpression of human epidermal growth factor receptor-2 (HER2), an 
oncogene, is associated with poor prognosis in breast cancer (Yarden, 2001).  
Both lifestyle and inherent factors could have an impact on cancer susceptibility.  
In order to better understand the biological processes of cancer, it is 
important to identify driver mutations that contribute to carcinogenesis 
(Mwenifumbo & Marra, 2013). Discovering common genetic aberrations could 
lead to revolutionizing the understanding of cancer biology and improving 
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targeted therapy strategies.  For example, identifying BRAF V600E, an activating 
mutation prevalent in 50-70% of all melanomas, has shed light on its underlying 
molecular mechanisms in the constitutive activation of MAPK signaling and has 
allowed for the development of BRAF pharmaceutical inhibitors (Fang, 
Hutchinson, Deng, & Green, 2016; Whipple & Brinckerhoff, 2014).  Identification 
of other recurrent genetic alterations, such as in-frame deletion of EGFR exon 19 
E746-A750 in non-small cell lung cancer (Cooper, Lam, O’Toole, & Minna, 2013) 
and chromosomal gain at 3q in cervical squamous cell carcinoma (Thomas et al., 
2014), have also reaped benefits in gaining insight into their genetic mechanisms 
and improving the efficacy of cancer treatment (Pfeifer & Besaratinia, 2009).  
While somatic mutations of each type of cancer are highly heterogeneous 
despite the same tissue of origin, next-generation sequencing has given the 
means to discover somatic mutations that influence pathways and deregulate cell 
and tissue homeostasis (Mwenifumbo & Marra, 2013). Expanding the catalogue 
of cancer-related DNA sequence changes will lead to deciphering the mutational 
landscape of different types of cancer (Pfeifer & Besaratinia, 2009). As more 
significant driver mutations and cancer genes get catalogued and identified, 
characterization of cancer subtypes and personalization of cancer therapy will 
greatly advance in the next five to ten years (Mwenifumbo & Marra, 2013). 
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Assessing the Risk of Second Malignant Neoplasms  
 Although the incidence of childhood cancer is extremely low, the 
prevalence of pediatric cancer survivors has increased over the past 30 years 
(Robison & Hudson, 2014). While the increase of survivors reflects the improved 
efficacy of childhood cancer therapy, survivors are still at high risk of second 
malignant neoplasms (SMNs) due to the harsh toxic treatments used to treat 
their first cancer (Robison & Hudson, 2014). Radiation therapy (RT), which uses 
focal, fractionated ionizing radiation (IR), a known mutagen, is often associated 
with SMNs (Sherborne et al., 2015). However, both the genetic consequences of 
IR exposure from RT and the impact of genetic background on SMN risk are 
poorly characterized.  
 In order to identify significant genetic events related to treatment-induced 
SMNs, we identified single nucleotide variants (SNVs) from SMNs of two 
pediatric cancer survivors by performing whole exome sequencing (WES) and 
comparing the differences between their sarcoma DNA to their corresponding 
germline control DNA.  From a comprehensive list of somatic variants found in 
patient tumor samples via WES, we were able to further analyze and identify 
potentially deleterious driver mutations by using predictor programs available 
online and categorizing each potential driver mutation based on relative risk. 
Furthermore, to characterize the influence of genetic background on IR-
induced tumorigenesis, we established a validation cohort of childhood cancer 
survivors who were diagnosed with subsequent treatment-induced cancers.  
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Because germline mutations in tumor suppressor gene TP53 are known to be 
indicative of genetic susceptibility to SMNs (Malkin et al., 1992), Sanger 
sequencing was performed on the germline of these patients to evaluate whether 
there is a higher prevalence in inherent polymorphisms of TP53 among radiation-
induced SMN patients.  Our validation cohort indicated that there is an increase 
in the recurrence of germline TP53 polymorphisms in both the proline-rich 
domain and DNA binding domain of the gene compared to the population.  These 
observations suggest screening for germline mutations in TP53 in pediatric 
cancer survivors could facilitate in identifying their genetic susceptibility to 
developing SMNs and possibly modifying therapies for individuals who harbor 
this alteration, especially to those who were unaware of their predisposition. 
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METHODS 
 
Whole Exome Sequencing 
Whole exome sequencing was performed using the NimbleGen Human 
exome v3.0 kit.  Captured material was indexed and sequenced on the Illumina 
GAII and HiSeq2000 platform at the Institute for Human Genetics at UCSF. 
Successfully sequenced reads were then mapped to the human reference 
genome (GRCh37) using GATK best practices. MuTect was used for somatic 
mutation detection. Annovar was used for variant annotation and to filter known 
human mutations to produce a cleaner list of variants. Mutation Assessor, SIFT, 
and PROVEAN were used to assign functional predictions.  Validation of a 
subset of somatic variants by Sanger sequencing confirmed 92% of SNVs (23 of 
25 tested). 
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Germline TP53 analysis of pediatric cancer survivors with subsequent 
SMNs 
 
To determine if there is a higher rate of polymorphisms of TP53 in 
pediatric cancer survivors with subsequent SMNs, we selected a validation 
cohort of 41 patients that are registered in the Childhood Cancer Survivor Study 
(CCSS), all of whom are pediatric cancer survivors with radiation-induced second 
cancers. The validation cohort consisted of patients who were initially treated of 
cancers such as Hodgkin lymphoma, sarcomas, and CNS tumors and developed 
SMNs following radiation therapy such as infiltrating ductal carcinoma of the 
breast and sarcomas. Furthermore, none of these survivors are known to be 
suffering from any known a hereditary tumor predisposition syndrome, such as 
Li-Fraumeni, Neurofibromatosis I, Tuberous Sclerosis, Neurofibromatosis 2, and 
Ataxia Telangiectasia).  
Polymerase chain reaction (PCR) was performed on the validation cohort 
to prepare for Sanger sequencing. Sequencing primers, as shown in Table 1, 
were used for PCR to screen 41 patients for variants in exons 2-11 of TP53. All 
of these primers were designed using Primer3 and checked using Blat and In 
Silico PCR from the UCSC Genome Bioinformatics site.  
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Table 1. List of TP53 sequencing primers. Primers listed were used to 
perform PCR for Sanger sequencing on exons 2-11 of TP53. F (Forward); 
R(Reverse). All of the primers used were individually designed using 
Primer 3 and validated using blat and In-Silico PCR.  
Exon Primer sequences 5’-3’ 
2 F: CAGCCATTCTTTTCCTGCTC 
  R: AGCCCAACCCTTGTCCTTAC 
3 & 4 F: TGAGTGGATCCATTGGAAGG 
  R: GCCAAAGGGTGAAGAGGAAT 
  F: CCCCTCTGAGTCAGGAAACA 
  R: GCCAAAGGGTGAAGAGGAAT 
5 F: CTCTCTAGCTCGCTAGTGGGT 
  R: CGAAAAGTGTTTCTGTCATCCAAAT 
6 F: GCCATGGCCATCTACAAGCA 
  R: TGGGGTTATAGGGAGGTCAAA 
5 & 6 F: GCCGTCTTCCAGTTGCTTTA 
  R: CTTAACCCCTCCTCCCAGAG 
7 F: ACAGGTCTCCCCAAGG 
  R: AAACTGAGTGGGAGCAGTAAGGAGA 
  F: CCTGCTTGCCACAGGTCT 
  R: TGATGAGAGGTGGATGGGTAG 
  F: TAACCCCATGAGATGTGCAA 
  R: GGGATGTGATGAGAGGTGGA 
8 F: GGACAAGGGTGGTTGGGAGTAGA 
  R: CCCAATTGCAGGTAAAACAGTCAAG 
9 F: GCGCACAGAGGAAGAGAATC 
  R: TGTCTTTGAGGCATCACTGC 
10 F: CTGGGCAACAGAGTGAGACC 
  R: CACTGAGGCAAGAATGTGGTT 
  F: CAGTTTCTACTAAATGCATGTTGCT 
  R: ATACACTGAGGCAAGAATGTGGTTA 
11 F: GATTTGAATTCCCGTTGTCC 
  R: CCACAACAAAACACCAGTGC 
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RESULTS 	
Identification and Classification of Potential Driver Mutations 
We identified potential driver mutations from non-silent variants found by 
WES in both Patient 1 and Patient 2 tumor samples by matching the gene and 
location of variant to the COSMIC cancer gene census (August 2015). While we 
obtained one tumor sample from Patient 1, we obtained two samples from 
Patient 2—samples A and B—from two distinct locations of the same tumor. 
SNVs that have been previously annotated in COSMIC were categorized based 
on criteria established by Murugaesu et al. (2015). After the SNV was validated 
to be a tumor suppressor gene via COSMIC, we proceeded to use three 
computational approaches—Sift, Polyphen, and MutationTaster—to predict the 
possible damaging effects of the mutation. A variant would be classed as 
Category 1, or high confidence driver mutation, if two of the three programs 
predicted the specific variant to be deleterious. If it did not match the criteria, then 
the proximity of the SNV to other mutation entries in COSMIC was considered. If 
there were more than 3 other entries listed on the COSMIC database within 15 
bps of the variant, then it would be classed as Category 2, or putative driver 
mutation. If it failed to be classed in any of criteria described, then it would be 
classified as Category 3, or low confidence driver mutation.  If the gene was 
determined to be a dominant oncogene according to COSMIC, then it would 
automatically be Category 1 if there were more than 3 entries of the same 
mutation in COSMIC. If there were less than three identical matches of the 
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variant, then it would be classed as Category 2 or 3 based on the same criteria 
as tumor suppressor genes. If the variant was not entered in the COSMIC gene 
census, then it would be classed a Category 2 if two out of the three predictor 
programs indicated the SNV to be harmful, otherwise Category 3. All other 
mutations were classified as Category 4, or mutations of unknown significance. 
Deletions and insertions were not categorized based on the criteria described 
above. However, indels were validated on COSMIC and checked for deleterious 
effects on MutationTaster. In addition, the number of entries on COSMIC within 
15 base pairs of each indel were counted.  
Table 2 displays high category (Category 1-3) SNVs and indels with either 
frameshift mutations or have more than three entries in COSMIC gene census 
within 15 base pairs. We found two high confidence driver mutations, one 
putative driver mutation, and one low confidence driver mutation in Patient 1. 
Patient 1 also had two indels with potential driver mutation characteristics. In 
Patient 2, there are two high confidence driver mutations, one putative driver 
mutation, and one low confidence driver mutation in both tumor samples A and 
B, one low confidence driver mutation exclusively in tumor sample A, and one 
high confidence and one low confidence driver mutation exclusively in tumor 
sample B. There are also two frameshift deletions exclusively in tumor A of 
Patient 2 and two frameshift deletions exclusively in tumor B of Patient 2. 
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Table 2: Overview of potential driver mutations found in Patient 1 and 
Patient 2 with SNM. 15bp (number of mutations found in COSMIC within 15 
base pairs of variant). N/A (program does not recognize the variant or program 
does not provide information on variant). Driver mutations listed on the table 
have all been previously identified in COSMIC cancer gene census (September 
2015). Driver mutations have been categorized, according to criteria established 
by Murugaesu et al. Patient 1 has two high confidence driver mutations 
(Category 1), Patient 2 has three high confidence driver mutations from both 
sample A and B. Through this classification process, we can better understand 
which gene mutations are responsible for tumorigenesis of SMNs.  
Patient 1 only 
Gene Nucleotide Category SIFT Polyphen Mutation Taster 15bp 
CSMD1 G7802A 3 tolerated probably damaging 
poly- 
morphism 0 
GRIK3 G2518A 2 N/A Benign disease causing 4 
LILRB1 1417_1419del - N/A N/A 
poly- 
morphism 5 
MTRR G364A 1 tolerated probably damaging 
disease 
causing 3 
NCOA2 G3523T 1 N/A probably damaging 
disease 
causing 1 
SMAD7 627_628insC - N/A N/A 
disease 
causing 6 
Patient 2 both tumor samples A and B 
Gene Nucleotide Category SIFT Polyphen Mutation Taster 15bp 
COL4A3 G3476A 2 N/A benign poly-morphism 23 
MAATS1 C1813T 1 damaging N/A disease causing 0 
MOV10L1 C656T 1 N/A probably damaging 
disease 
causing 10 
NTSR2 C868T 2 tolerated probably damaging N/A 5 
Patient 2 tumor A only 
Gene Nucleotide Category SIFT Polyphen Mutation Taster 15bp 
ETV3L C407T 2 N/A N/A poly-morphism 4 
FBN3 2259delC - N/A N/A disease causing 4 
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RQCD1 350delT - N/A N/A disease causing 3 
Patient 2 tumor B only 
Gene Nucleotide Category SIFT Polyphen Mutation Taster 15bp 
CYHR1 430delG - N/A N/A disease causing 4 
NALCN G2081A 1 tolerated probably damaging 
disease 
causing 11 
TCF20 737_739del - N/A N/A disease causing 3 
 
  
From the potential driver mutations found in SMN sarcomas from Patient 1 
and Patient 2 via WES, we hypothesize that the top two driver mutation 
candidates are SMAD7 and NCOA2. In addition to the high confidence driver 
mutation (Category 1) of NCOA2, a gene that encodes a transcriptional 
coactivator for nuclear receptors known to be mutated in sarcomas, Patient 1 
also harbor a frameshift mutation, a known deleterious genetic event, in SMAD7, 
a gene that encodes a protein mediator in the TGF-B tumor suppressor pathway 
known to be abnormally expressed in various cancers.
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Germline TP53 Validation Cohort  
 
 An accumulation of genetic mutations is known to induce cancer 
pathogenesis (Almeida & Barry, 2011). Most of these alterations are located 
within the following three categories of genes: proto-oncogenes, tumor 
suppressor genes, or DNA repair genes (Cooper et al., 2013). Proto-oncogenes 
control cell division and growth while tumor suppressor genes suppress cell 
growth and division (Pfeifer & Besaratinia, 2009). Mutations within these three 
categories of genes have a direct correlation with oncogenesis (Iengar, 2012).  
The tumor suppressor protein p53, encoded by gene TP53, is in the 
center of regulation of cell cycle checkpoints, apoptosis, DNA repair, cellular 
metabolism, and senescence (Gibbons, Byers, & Kurie, 2014). When genotoxic 
stress is induced on the cell, stabilization of p53 promotes the transcription of 
genes that plays a role in cell-cycle arrest, apoptosis, and DNA repair (Liu, Song, 
& Xu, 2010). Mutations of p53 is known to have a driving role in tumor 
progression by deregulating these important mechanisms of cancer suppression 
(Sigal & Rotter, 2000). 50% of all human cancers are known to have p53 
mutations, with 74% of these mutations being missense mutations (Meek, 2015).  
P53 mutations are mainly missense mutations that not only inactivate the 
normal protein function, but also gain altered functions that further promote 
oncogenesis (Liu et al., 2010, p. 53). Common missense mutations occur in the 
DNA binding domain (exons 5-8) that changes the conformation of the protein, 
interfering with the binding domain and its ability to regulate transcription of 
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downstream genes (Sigal & Rotter, 2000). Frequent somatic mutations within this 
hotspot include R175H, commonly detected in breast cancer (Byler et al., 2014), 
and R249S in liver cancer (Goldstein et al., 2011). Germline p53 gene mutations 
are mainly associated with Li-Fraumeni syndrome, a familial autosomal dominant 
predisposition to a wide array of cancers, mainly early onset of sarcomas, gliomas, 
and breast carcinomas, with 57% probability of developing a second cancer in the 
next 30 years (Malkin et al., 1992). While families with Li-Fraumeni Syndrome 
(LFS) are closely monitored and studied, those who lack family histories of LFS 
cancers but harbor de novo tp53 mutations are poorly characterized (Kilpivaara & 
Aaltonen, 2013). However, there has been emerging evidence that germline TP53 
mutations not related to LFS also have oncogenic roles in different cancer types 
(Kamihara, Rana, & Garber, 2014).  
To identify germline mutations of TP53 in non-LFS patients with second 
malignant neoplasms (SMN), we sequenced the germline DNA of 41 patients 
from a validation cohort comprised of pediatric cancer survivors with subsequent 
neoplasms registered in CCSS. Sanger sequencing was performed on exons 2-
11 of TP53, and we observed a synonymous mutation in exon 6 codon 213 
(A639G in the gene, R213R in the protein) in 4 out of 37 patients (11%). This 
single nucleotide polymorphism rs1800372 has a minor allele frequency of 0.5% 
in the general population 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1800372). This 
significant increase in frequency of this SNP in the validation cohort compared to 
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the general population leads us to believe the mutation may have a deleterious 
effect on the DNA binding domain and on the genetic susceptibility to SMN. A 
second germline variant identified in this validation cohort was G215C in exon 4 
(R72P in the protein), which was present in 6 patients and mutually exclusive 
with the germline A639G variant, resulting in a total of ten out of 38 evaluable 
patients (26%) harboring a germline TP53 variant. While the R72P polymorphism 
is common in the general population (Vietri et al., 2007), the A639G TP53 variant 
is uncommon in the general population but significantly enriched in our cohort. 
Shown in Figure 1 are sequencing chromatograms from four pediatric cancer 
survivors who harbor germline variant A639G and six individuals demonstrating 
variant G215C. Both sets of variants are compared to the normal control DNA on 
the first row as reference. These chromatograms demonstrate clear 
heterozygous mutations harbored by patients in the validation cohort.    
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Figure 1. Representative SMN samples showing TP53 mutations found in 
the validation cohort of pediatric cancer survivors with SMNs. Synonymous 
mutation A639G was identified in four patients—VS 38, VS 35, VS 39, VS07; 
Missense mutation R72P was harbored in six patients mutually exclusive from 
patients who harbor A639G—VS32, VS08, VS24, VS27, VS29, VS41. These 
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SMN patient samples were obtained from the validation cohort of pediatric 
patients registered in CCSS.
	18 
DISCUSSION 
Identification of Deleterious Driver Mutations 
 Cancer development involves stages of initiation, promotion, and 
progression (Weinberg, 2013). These stages are characterized by aberrant 
genetic events that accumulate over time. To identify possible significant genetic 
events related to radiation-induced malignancies, WES was performed on two 
pediatric cancer survivors with SMNs, Patient 1 and Patient 2. Through WES, we 
identified a frameshift deletion in codon 209 of gene SMAD7 in Patient 1, which 
has been found to be implicated in pancreatic, gastric, skin, breast, liver, and 
prostate cancer (Stolfi, Marafini, De Simone, Pallone, & Monteleone, 2013, p. 7). 
As shown in Figure 2, codon 209 is part of the N-terminal MAD homology 1 
domain(MH1), which is related to protein regulation and stability. SMAD7 is part 
of the Smad protein family that is activated via phosphorylation by TGF-B Type I 
receptor (Yan & Chen, 2011). Transforming Growth Factor (TGF-B) is a tumor 
suppressor cytokine that is known to inhibit proliferation and promote apoptosis 
in normal cells (Luo, Li, Lv, & Huang, 2014). On the other hand, TGF-B signaling 
is also known to drive late cancer cells to promote epithelial-mesenchymal 
transition that leads to invasion and metastasis (Stolfi et al., 2013). Studying the 
dual contradicting roles of TGF-B has paved the way of understanding its 
downstream mechanisms and discovering intracellular signal proteins, among 
which Smad7 is a negative regulator of the TGF-B cascade signaling pathway 
(Stolfi et al., 2013). Smad proteins are grouped into three classes: Receptor 
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activated Smads, inhibitory Smads, and common-mediator Smads (Luo et al., 
2014). 
.  
Figure 2. Structure of Smad7. We detected a deletion of two nucleotides in 
codon 209 in the SMN of Patient 1 located at the N-terminal of the protein. The 
N-terminus interacts with the MH2 domain while inhibiting TGF-B Type I receptor. 
Post-translational modifications occur in the N-terminus of the protein, regulating 
protein stability and functions (Yan & Chen, 2011). 
 
 As seen in Figure 3, TGF-B is a cytokine that signals through its 
interactions with its membrane-bound receptors, TGF-B Type I (TBRI) and TGF-
B Type II (TBRII) (Stolfi et al., 2013).  These receptors interact with regulatory 
Smad (R-Smad) proteins and Co-smad proteins to promote cell-cycle arrest, 
differentiation, or apoptosis (Stolfi et al., 2013). Smad7, an I-smad, suppresses 
TGF-B signaling in both the cytoplasm and the nucleus via various mechanisms. 
In the cytoplasm, Smad7 blocks R-Smad phosphorylation, promotes degradation 
of TGF-B RI, and suppresses TGF-B RI activation by dephosphorylation (Stolfi et 
al., 2013). In the nucleus, Smad7 inhibits the formation of R-Smad/Smad4 
complexes and disrupts the R-Smad/Smad4 complexes from binding to DNA 
(Stolfi et al., 2013).  
   
2 X. Yan and Y.-G. Chen
Figure 1 Structure and modifications of Smad7
Smad7 contains a conserved MH2 domain, but lacks the C-terminal SXS residues in R-Smads. Smad7 undergoes various post-translational modifications. The stability of Smad7 is controlled by a
balance between ubiquitination (Ub) and acetylation (Ac). Ubiquitin E3 ligases, including Smurfs, Jab1, Arkadia and others, induce the ubiquitination and degradation of Smad7. The acetyltransferase
p300 acetylates Smad7 at Lys64 and Lys70, the sites that Smurf1 also ubiquitinates, leading to inhibition of ubiquitination and enhanced stability of Smad7. On the other hand, the deacetylases
HDAC1 and SIRT1 are able to deacetylate Smad7. MPK38 phosphorylates Smad7 at Thr96, leading to its cytoplasmic distribution. Ser249 in Smad7 is also reported to be phosphorylated (P), which
might not regulate TGF-β signalling but rather affects the transcriptional activity of Smad7. Moreover, PRMT1 methylates (Me) Smad7 at Arg38 with unclear functions.
and Smad4 [1,18] (Figure 1). The N-termini between Smad6 and
Smad7 share a similarity of only 36.7%. The interaction between
I-Smads and the type I receptor also plays significant roles for
their inhibitory effects (see below). According to biochemical
studies and homology-based structural models [19], the L3 loop–
L45 loop interaction and the basic groove–GS region interaction
are also important for Smad7 to associate with TβRI, but
the specificity is not determined by the L3 loop in this case.
Mutagenesis studies revealed that the basic residues in the L3 loop
of Smad7 (Lys401 and Arg409) are essential for its association with
both TβRI and BMPRIB (BMP type I receptor), and mutations
of Lys312 and Lys316 in the basic groove would inhibit the binding
of Smad7 to TβRI, but not to BMPRIB. Besides the L3 loop,
residues 331–361 and 379–387 in Smad7 form a three-finger-like
structure [20], providing an alternative surface for its binding to
the type I receptors. However, Smad6 lacks the three-finger-like
structure and associates with the type I receptors mainly through
the basic groove surface. In addition, the N-terminus of Smad7
physically interacts with its MH2 domain and is required for
the maximal inhibitory effect of Smad7 on TβRI, but not on
BMPRIB, indicating that Smad7 may exploit distinct ways in
binding to different type I receptors [21,22].
Post-translational modifications are involved in regulating
protein stability and functions. Smad7 recruits several HECT
(homologous with E6-associated protein C-terminus)-type E3
ubiquitin ligases (including Smurf1/2, where Smurf is Smad
ubiquitination-related factor) to induce the ubiquitination and
degradation of TβRI, during which process Smad7 itself would
be also ubiquitinated and degraded [23–25]. Jab1/CSN5, which
is a component of the COP9 signalosome complex, was reported
to regulate the stability of Smad7 and release its inhibitory effect
on TGF-β signalling [26] (Figure 1). Arkadia has been shown
to ubiquitinate and degrade Smad7, and Axin acts as an adaptor
protein in this process [27,28]. In addition, the acetyltransferase
p300 can acetylate Smad7 on two lysine residues (Lys64 and
Lys70), which are critical for Smurf1-mediated ubiquitination of
Smad7 [29]. Acetylation of Smad7 inhibits its ubiquitination,
resulting in enhanced protein stability. On the other hand, HDAC1
(histone deacetylase 1) and SIRT1 (sirtuin 1) were reported
to deacetylate Smad7 [30,31]. Thus the stability of Smad7 is
regulated by a balance between acetylation and ubiquitination.
Furthermore, PRMT1 (protein arginine N-methyltransferase 1)
was shown to methylate Smad7 at Arg38 with unclear functions
[32], and Smad7 was also found to be phosphorylated at Ser249 by
an unknown kinase, which might not regulate TGF-β signalling,
but rather affects the transcriptional activity of Smad7 [33].
Moreover, a recent study showed that MPK38 (murine protein
serine/threoni e kinase) phosphorylates Smad7 at Thr96, resulting
in its redistribution from the nucleus to the cytoplasm [34].
SMAD7 ACTS AS A KEY NEGATIVE REGULATOR OF TGF-β
SIGNALLING
TGF-β signalling is finely modulated both temporally and
spatially by diverse regulators, among which Smad7 functions
as a key negative regulator [4,14]. Smad7 antagonizes TGF-β
signalling through multiple mechanisms (Figure 2). It was firstly
shown to form a stable complex with TβRI, thus inhibiting
the recruitment, and thereby phosphorylation, of R-Smads and
R-Sm d–Smad4 complex formation [35–37]. Recently, we
showed that BAMBI (BMP and activin membrane-bound
inhibitor) is able to form a ternary complex with activated TβRI
and Smad7, and synergizes with Smad7 to antagonize TGF-β
signalling by interfering with the recruitment of R-Smads [38].
Extensive studies have documented that Smad7 functions as an
adaptor to recruit WW-HECT-type E3 ubiquitin ligases (where
WW refers to the WW domain) and induce the degradation of
TβRI (Table 1). For insta ce, Smad7 recruits Smurf proteins on
to the plasma membrane, where they induce TβRI endocytosis
through caveolin-positive vesicles, leading to the ubiquitination
and degradation of TβRI in either the lysosomal or proteasomal
pathways [23–25,39]. Upon TGF-β signalling, Smad7 associates
with Smurf1/2 through its PY motif in the nucleus, together they
translocate into the cytoplasm, and Smad7 then binds to activated
TβRI [23–25]. Meanwhile, the N-terminus of Smad7 may
recruit the E2-conjugating enzyme UbcH7 (ubiquitin-conjugating
enzyme 7), and facilitate Smurf2 activity and TβRI degradation
[40]. It has been reported that HSP90 (heat-shock protein
90) could enhance Smad7/Smurf2-mediated ubiquitination and
degradation of TβRI [41]. Moreover, Smad7 has also been
reported to recruit another two HECT-type E3 ubiquitin ligases,
NEDD4–2 and WWP1/Tiul1 [42–44].
In addition to recruiting E3 ubiquitin ligases to facilitate
receptor degradation, Smad7 can engage the phosphatase
GADD34 (growth-arrest and DNA-damage-inducible protein
34)-PP1c (protein phosphatase 1c) to dephosphorylate TβRI [45].
Smad7 also recruits PP1α to control ALK1 (activin receptor-
like kinase 1) (another TβRI receptor) activity in endothelial
cells [46]. Furthermore, many other proteins have been found to
c⃝ The Authors Journal compilation c⃝ 2011 Biochemical Society
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Figure 3. Schematic of the transforming growth factor (TFG-B) signaling 
pathway. When TGF-B binds to its type II receptor, TGF-B type I forms a 
receptor complex with TGF-B RI. When the receptor complex is activated, TGF-B 
RI phosphorylates an R-smad, which allows the R-smad to bind to Smad4. This 
complex moves into the nucleus to bind to the DNA and promotes the 
transcription of target genes. Smad7 antagonizes the signaling pathway in both 
the cytoplasm and the nucleus, as indicated by * and ** (Stolfi et al., 2013). 
  
 In addition to acting as an inhibitor in the TGF-B signaling pathway, 
Smad7 also promotes cancer progression (Luo et al., 2014). On one hand, there 
is an increase in the expression of SMAD7 in a variety of cancers, such as 
breast, colorectal, and prostate cancers (Luo et al., 2014). Furthermore, an over-
expression of SMAD7 is correlated to poor prognosis in colon adenocarcinoma 
(Luo et al., 2014). Upregulation of SMAD7 in these cancers indicate that SMAD7 
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Figure 1. Schematic overview of the transforming growth factor (TGF)-β signaling 
pathway. Binding of TGF-β to its type II receptor (TGF-β RII) (1) attracts the TGF-β type I 
receptor (TGF-β RI) (2) and leads to formation of a receptor complex (3) and 
phosphorylation of TGF-β RI (4). Thus activated, TGF-β RI in turn phosphorylates a 
receptor-activated Smad (R-Smad) (4), allowing this protein to associate with Smad4 and 
move into the nucleus (5). Once in the nucleus, this Smad complex associates with  
DNA-binding proteins (6) to activate the transcription of specific target genes (7). Negative 
regulators of this signaling pathway are indicated in red. * and ** indicate mechanisms by 
which Smad7 antagonizes TGF-β signaling in the cytoplasm and in the nucleus respectively. 
 
Smad7, also known as mothers against decapentaplegic homolog 7 (MADH7) is located in the 
chromosome 18 in both human (i.e., 18q21.1) and mouse (i.e., 18 51.06 cM) and codifies a protein 
with 426 aa residues. Smad7 protein structure consists of an N-terminal MAD homology 1 (MH1) 
domain lacking the DNA-binding domain present in Smad4 and most of R-Smads, followed by a  
non-conserved region called li ker and a highly conserved C-termin l MAD-Homology 2 (MH2) 
domain that lacks the SSXS phosphorylation motif present in R-Smads, identified as the target of 
receptor-depende t phosphoryla on (please see refs. [11,12] for more detailed information). 
Smad7 antagonizes TGF-β signaling through multiple mechanisms both in the cytoplasm and in the 
nucleus. For example, Smad7 blocks R-Smad phosphorylation by occupying the catalytic domain of 
TGF-β RI [13,14]. Smad7 also induces degradation of TGF-β RI through recruitment of Smurf1/2 or 
Nedd4-2, some of the E3 ubiquitin ligases that target activated TGF-β receptor complexes for 
degradation via proteasome [15–17]. Moreover, Smad7 interacts with growth arrest and DNA damage 
protein (GADD34), a regulatory subunit of the protein phosphatase 1 (PP1) holoenzyme, thereby 
leading to TGF-β RI inactivation by dephosphorylation [18]. At nuclear level, Smad7 can exert its 
inhibitory activity by disrupting the formation of functional R-Smad/Smad4 complexes as well as their 
binding to DNA [19]. 
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inhibited the tumor suppressor role of TGF-B signaling (Luo et al., 2014). 
However, other tumors also indicate a deletion of the gene can promote invasion 
and metastasis, shown in liver, breast, and skin cancer (Yan & Chen, 2011). 
While Smad7’s pro- and anti-tumor roles are contradictory, this is not surprising 
given the dual roles of TGF-B signaling pathway in different stages of cancer 
(Stolfi et al., 2013).  
 Given the complex role of Smad7 in TGF-B signaling pathway, any 
genetic aberrations on this gene could have a deleterious effect on cancer cells, 
promoting malignancies and cancer progression. Furthermore, due to the 
damaging consequences of frameshift mutations (Iengar, 2012), the Smad7 
protein in Patient 1 is most likely abnormal, potentially leading to secondary 
tumor formation post-RT.  
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Analysis of TP53 Polymorphisms found in Second Malignant Neoplasms 
 Cancer is a disease that results from an accumulation of cells that are 
unable to maintain homeostasis due to irregular genetic and epigenetic events 
(Cooper et al., 2013). Sequencing has paved the way to identifying and 
understanding the various genetic alterations that occur in cancer genomes 
(Stratton, 2011). Through genomic sequencing, tumor suppressor gene TP53 
has been confirmed to be the most mutated in human cancers, mutated in over 
50% of human cancers (Bieging & Attardi, 2012). The majority of these mutations 
has been classified as missense mutations, mutations that change a single 
amino acid that result in the expression of a mutated protein that potentially leads 
to deleterious effects (Goldstein et al., 2011).  
While the role of TP53 has been widely studied in various cancers, it is still 
poorly characterized in SMN patients (Sherborne et al., 2015). To identify 
possible recurrent TP53 polymorphisms and mutations in our validation cohort of 
SMN patients, Sanger sequencing was performed on exons 2-11 of the tumor 
suppressor gene. This study identified the recurrent SNP rs1800372 in TP53, as 
shown in Figure 4. Although this SNP results in a synonymous mutation and 
does not change the sequence of the encoded protein, it has been correlated 
with poor prognosis in primary breast cancer (Berns et al., 1998). Furthermore, 
synonymous mutations, or “silent” mutations, have also been found to be driver 
mutations in human cancers, contributing to the tumor phenotype (Supek, 
Miñana, Valcárcel, Gabaldón, & Lehner, 2014). Silent mutations are known to 
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alter translational accuracy by affecting mechanisms related to mRNA 
conformation, mRNA translation, and pre-mRNA splicing (Supek et al., 2014).  
A second germline variant identified in this validation cohort is G215C in 
exon 4, or R72P in the protein, in 6 additional patients. While this polymorphism 
is quite common in the general population, this polymorphism has a profound 
change on the primary structure of the p53 protein. As indicated in Figure 4, the 
variant is located on the proline-rich domain, a region required to induce 
apoptosis (Pim & Banks, 2004). It has been previously shown that the Arg72 
variant demonstrated higher efficiency at inducing apoptosis than the Pro72 
variant, indicating higher risk for neoplastic formation for those who harbor the 
variant (Vietri et al., 2007).  
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Figure 4. Localization of TP53 mutations in relation to the mature functional 
region of p53 protein.  Note the locations of germline variants found in 37 
pediatric cancer patients with radiation-induced SMNs. The first recurrent variant 
found from the validation cohort is R213R, a synonymous mutation located on 
exon 6, which is part of DNA binding domain of protein p53, also known as the 
“hotspot” of p53 mutations implicated in cancer. P72R variant was also identified 
in the validation cohort, which is located on exon 4 that is part of the proline-rich 
domain on the functional protein p53. Although a common polymorphism in the 
general population, it is implicated in poor apoptosis induction, promoting cell 
proliferation and suppressing anti-tumor properties.  
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Importance of Cancer Genome Sequencing 
 
 Next-generation sequencing, or second-generation sequencing, has 
revolutionized the understanding of the molecular biology of cancer (Pfeifer & 
Besaratinia, 2009). These large scale sequencing studies, such as WES, have 
provided the means to identify driver mutations, to discover mutational 
signatures, and to pave the way of personalized medicine (Stratton, 2011). As 
exhaustive sequencing of cancer genomes is under way, the result of these 
analyses will not only change our understanding, but it will also lead to new 
target therapies to treat and to hopefully prevent the disease altogether 
(Mwenifumbo & Marra, 2013). This new comprehensive data will help scientists 
and clinicians predict cancer behavior, tumor progression and responses to 
therapies, such as radiation therapy (Kilpivaara & Aaltonen, 2013).  
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